Real-world (RW) risk of recurrence among patients (pts) diagnosed with stage II-III HR+/HER2-early breast cancer (EBC) treated with endocrine therapy (ET) in the US.

Rohan Chandrakant Parikh; Abigail Elaine Hitchens; Pedram Razavi; Mehnaj Ahmed; Ashley Roush; Rohan Chandrakant Parikh; Abby Hitchens; Sherry Shen; Anton Safonov; Komal L. Jhaveri; Mark E. Robson; Nancy Walker Peacock; Yanjun Ma; Elizabeth Chertow Santarsiero; Vaidyanathan Ganapathy; Rohan M. Shah; Adaeze Q. Amefule; Agnes Lteif; L. Johnetta Blakely

Real-world (RW) risk of recurrence among patients (pts) diagnosed with stage II-III HR+/HER2-early breast cancer (EBC) treated with endocrine therapy (ET) in the US.

Razavi, P., Ahmed, M., Roush, A., Parikh, R., Hitchens, A., Shen, S., Safonov, A., Jhaveri, K. L., Robson, M. E., Peacock, N. W., Ma, Y., Santarsiero, E. C., Ganapathy, V., Shah, R. M., Amefule, A. Q., Lteif, A., & Blakely, L. J. (2024). Real-world (RW) risk of recurrence among patients (pts) diagnosed with stage II-III HR+/HER2-early breast cancer (EBC) treated with endocrine therapy (ET) in the US. Journal of Clinical Oncology, 42(16).

Copy citation